Skip to main content

Research News

  • New FGFR inhibitors exhibit potential against cholangiocarcinoma

    Targeting FGFR has recently emerged as a promising strategy in the treatment of cholangiocarcinoma (CCA), a very aggressive rare malignancy. At ESMO Congress 2022, two new agents were added to the list of FGFR inhibitors being investigated, showing some clinical benefits or potential in patients not previously treated with this anticancer drug class.

    Two early studies investigate the anticancer activity of derazantinib and RLY-4008 in patients with FGFR inhibitor-naive cholangiocarcinoma.

  • ​Malaria detection using AI is pressing priority, says Lancet

    ICMR-National Institute of Malaria Research scientists from India published an opinion in Lancet Regional Health Southeast Asia that India requires Artificial Intelligence (AI) based approaches into the current microscopy method for detection of Malaria.

  • New link recognised between infection during pregnancy and autism

    Infections in pregnant women have been linked to an increased risk of neurodevelopmental conditions, such as autism, in the child later in life. But it does not seem to be the infections themselves that cause autism, researchers from Karolinska Institutet in Sweden show in a study published in The Lancet Psychiatry.

  • Neutralizing antibodies from single COVID-19 booster steadily decline

    Neutralizing antibody levels against the original COVID-19 virus and omicron variants in vaccinated adults tend to decline by at least 15% per month after a single booster shot, a new study using serum from human blood samples suggests. 

    Data from two adults in the same study who had a dramatic loss in antibodies but received a second booster showed that the second dose completely restored antibodies to protective levels.

  • High BP may accelerate bone aging

    When high blood pressure was induced in young mice, they had bone loss and osteoporosis-related bone damage comparable to older mice, according to new research presented today at the American Heart Association’s Hypertension Scientific Sessions 2022 conference, held Sept. 7-10, 2022, in San Diego. The meeting is the premier scientific exchange focused on recent advances in basic and clinical research on high blood pressure and its relationship to cardiac and kidney disease, stroke, obesity and genetics.

  • AI based AlphaFold shows potential in drug discovery

    Over the past few decades, very few new antibiotics have been developed, largely because current methods for screening potential drugs are prohibitively expensive and time-consuming. One promising new strategy is to use computational models, which offer a potentially faster and cheaper way to identify new drugs.

  • In 2019, over 70 percent antibiotics used in India were unapproved

    ​An eye opening study published in Lancet which highlights, India consumed 72.7 percent of unapproved antibiotics products in 2019. India has also consumed 48.7 percent of Fixed Dose Combinations discouraged by the WHO.

  • Toxin discovered that kills bacteria in unprecedented ways

    Researchers at McMaster University have discovered a previously unknown bacteria-killing toxin that could pave the way for a new generation of antibiotics.

    The study, led by John Whitney at the Michael G. DeGroote Institute for Infectious Disease Research, shows that the bacterial pathogen Pseudomonas aeruginosa, known to cause hospital-acquired infections such as pneumonia, secretes a toxin that has evolved to kill other species of bacteria.

  • Myocarditis after COVID-19 vaccines remain rare

    A new study from Israel found that the risk of developing myocarditis among males ages 16 to 19 years was about 1 in 15,000 after third dose of the Pfizer-BioNTech COVID-19 vaccine, and the cases were rare and mild, according to new research published today in the American Heart Association’s flagship journal Circulation.

  • Stem Cell-Gene Therapy Shows Promise in ALS Safety Trial

    Cedars-Sinai investigators have developed an investigational therapy using support cells and a protective protein that can be delivered past the blood-brain barrier. This combined stem cell and gene therapy can potentially protect diseased motor neurons in the spinal cord of patients with amyotrophic lateral sclerosis, a fatal neurological disorder known as ALS or Lou Gehrig's disease.

    In the first trial of its kind, the Cedars-Sinai team showed that delivery of this combined treatment is safe in humans.

Subscribe to Research News